PharmaMar signed a licensing agreement with GP Pharm laying Lutrate marketed in Italy for the treatment of prostate cancer "CataloniaBio
Home ASSOCIATS D'SIGN BOARD Arxiu Juntes Comissió Financera Sol d'inscription match point legality Tutorial WEB Comentari about BioNews! BioNews! ENQUESTES Enquesta Qui Som? Contact informatio Membres match point Sitemap Serveis Convenis BIO Directori Ajuts Formació Enllaços Àrea Reports Private Bid NotÃcies DOCUMENTATION Arxiu 2010 Actualitat Experiències destacat Activitats Calendar
Zeltia announced this week that its subsidiary oncology PharmaMar has signed a licensing agreement with GP Pharm establishing PharmaMar match point distribute the drug in Italy GP Pharm Lutrate (leuprorelin).
Lutrate is a drug approved in 23 countries of the European Union for the treatment of prostate match point cancer and also has the approval of the redemption price. The contract terms state that PharmaMar Lutrate exclusive distributor in Italy and the revenue generated to pay a royalty to GP Pharm agreed.
PharmaMar plans to begin distribution Lutrate in Italy starting next October. At first marketing will start throwing the dosage of one month and is expected to expand further treatments three to six months.
This agreement is synergistic with commercial activity PharmaMar in other EU countries and is part of the company strategy to strengthen its sales network with new products to add to its portfolio. The agreement that the two companies have signed refers to the distribution of Lutrate and not to manufacture, which is responsible GP Pharm. Thus, this agreement does not involve any additional investment by PharmaMar, and use its existing infrastructure in Italy for the marketing of this drug.
Noticies growing number of companies included in the "Plan Profarma" Kern Pharma, generic firm, comes out one rep L'ICIQ Severo Ochoa accrediting match point a l'excel lència in Investigació 3D printed organs are already here Trifermed Establishes affiliate in Germany for operations in Central, Northern and Eastern match point Europe Iproteos walking l '"equity match point crowdfunding" Carlos Gallardo fitxa per Ysios després of deixar Funding opportunities Almirall R & D for companies in Programming ERDF 2014-2020
ELS propers Esdeveniments Fatal error: match point Call to undefined function ec3_get_events () in / docroot / wp-content / themes / hyperion / sidebar-footer.php on line 17
Home ASSOCIATS D'SIGN BOARD Arxiu Juntes Comissió Financera Sol d'inscription match point legality Tutorial WEB Comentari about BioNews! BioNews! ENQUESTES Enquesta Qui Som? Contact informatio Membres match point Sitemap Serveis Convenis BIO Directori Ajuts Formació Enllaços Àrea Reports Private Bid NotÃcies DOCUMENTATION Arxiu 2010 Actualitat Experiències destacat Activitats Calendar
Zeltia announced this week that its subsidiary oncology PharmaMar has signed a licensing agreement with GP Pharm establishing PharmaMar match point distribute the drug in Italy GP Pharm Lutrate (leuprorelin).
Lutrate is a drug approved in 23 countries of the European Union for the treatment of prostate match point cancer and also has the approval of the redemption price. The contract terms state that PharmaMar Lutrate exclusive distributor in Italy and the revenue generated to pay a royalty to GP Pharm agreed.
PharmaMar plans to begin distribution Lutrate in Italy starting next October. At first marketing will start throwing the dosage of one month and is expected to expand further treatments three to six months.
This agreement is synergistic with commercial activity PharmaMar in other EU countries and is part of the company strategy to strengthen its sales network with new products to add to its portfolio. The agreement that the two companies have signed refers to the distribution of Lutrate and not to manufacture, which is responsible GP Pharm. Thus, this agreement does not involve any additional investment by PharmaMar, and use its existing infrastructure in Italy for the marketing of this drug.
Noticies growing number of companies included in the "Plan Profarma" Kern Pharma, generic firm, comes out one rep L'ICIQ Severo Ochoa accrediting match point a l'excel lència in Investigació 3D printed organs are already here Trifermed Establishes affiliate in Germany for operations in Central, Northern and Eastern match point Europe Iproteos walking l '"equity match point crowdfunding" Carlos Gallardo fitxa per Ysios després of deixar Funding opportunities Almirall R & D for companies in Programming ERDF 2014-2020
ELS propers Esdeveniments Fatal error: match point Call to undefined function ec3_get_events () in / docroot / wp-content / themes / hyperion / sidebar-footer.php on line 17
No comments:
Post a Comment